|
|
| (8 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| |
| |authorTag=
| |
|
| |
|
|
| |
| <!--Overview-->
| |
|
| |
| |genericName= INDIUM IN 111 OXYQUINOLINE
| |
|
| |
|
| |
|
| |
| |aOrAn=
| |
|
| |
| a
| |
|
| |
| |drugClass=
| |
|
| |
|
| |
|
| |
| |indication=
| |
|
| |
| *Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes.
| |
|
| |
| *Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures.
| |
| |hasBlackBoxWarning=
| |
| Yes
| |
|
| |
| |adverseReactions=
| |
|
| |
|
| |
|
| |
| <!--Black Box Warning-->
| |
|
| |
| |blackBoxWarningTitle=
| |
| Title
| |
|
| |
| |blackBoxWarningBody=
| |
| <i><span style="color:#FF0000;">ConditionName: </span></i>
| |
|
| |
| * Content
| |
|
| |
| <!--Adult Indications and Dosage-->
| |
|
| |
| <!--FDA-Labeled Indications and Dosage (Adult)-->
| |
|
| |
| |fdaLIADAdult=
| |
|
| |
| =====Condition1=====
| |
|
| |
| *Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes.
| |
|
| |
| *Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process.
| |
|
| |
| *Indium In 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. Ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. If localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. If localization or diagnosis by these methods fails or is ambiguous, indium In 111 oxyquinoline labeled leukocyte imaging may be appropriate.
| |
|
| |
| ======Dosing Information======
| |
|
| |
| *The recommended adult (70 kg) dose of indium In 111 oxyquinoline labeled autologous leukocytes is 7.4 to 18.5 MBq, 200-500 µCi. Indium In 111 oxyquinoline solution is intended for the radiolabeling of autologous leukocytes. The indium In 111 oxyquinoline labeled autologous leukocytes are administered intravenously.
| |
|
| |
| *Imaging is recommended at approximately 24 hours post injection. Typically, anterior and posterior views of the chest, abdomen and pelvis should be obtained with other views as required.
| |
|
| |
| *Aseptic procedures and a shielded syringe should be employed in the withdrawal of indium In 111 oxyquinoline from the vial. Similar procedures should be employed during the labeling procedure and the administration of the labeled leukocytes to the patient. The user should wear waterproof gloves during the entire procedure. The patient's dose should be measured by a suitable radioactivity calibration system immediately before administration. At this time, the leukocyte preparation should be checked for gross clumping and red blood cell contamination.
| |
| <!--Off-Label Use and Dosage (Adult)-->
| |
|
| |
| <!--Guideline-Supported Use (Adult)-->
| |
|
| |
| |offLabelAdultGuideSupport=
| |
|
| |
| =====Condition1=====
| |
|
| |
| * Developed by:
| |
|
| |
| * Class of Recommendation:
| |
|
| |
| * Strength of Evidence:
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
|
| |
| <!--Non–Guideline-Supported Use (Adult)-->
| |
|
| |
| |offLabelAdultNoGuideSupport=
| |
|
| |
| =====Condition1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
|
| |
| <!--Pediatric Indications and Dosage-->
| |
|
| |
| <!--FDA-Labeled Indications and Dosage (Pediatric)-->
| |
|
| |
| |fdaLIADPed=
| |
|
| |
| =====Condition1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
| |
|
| |
| <!--Off-Label Use and Dosage (Pediatric)-->
| |
|
| |
| <!--Guideline-Supported Use (Pediatric)-->
| |
|
| |
| |offLabelPedGuideSupport=
| |
|
| |
| =====Condition1=====
| |
|
| |
| * Developed by:
| |
|
| |
| * Class of Recommendation:
| |
|
| |
| * Strength of Evidence:
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
|
| |
| <!--Non–Guideline-Supported Use (Pediatric)-->
| |
|
| |
| |offLabelPedNoGuideSupport=
| |
|
| |
| =====Condition1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
|
| |
| <!--Contraindications-->
| |
|
| |
| |contraindications=
| |
|
| |
| * Condition1
| |
|
| |
| <!--Warnings-->
| |
|
| |
| |warnings=
| |
|
| |
| * Description
| |
|
| |
| ====Precautions====
| |
|
| |
| * Description
| |
|
| |
| <!--Adverse Reactions-->
| |
|
| |
| <!--Clinical Trials Experience-->
| |
|
| |
| |clinicalTrials=
| |
|
| |
| There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| =====Body as a Whole=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Cardiovascular=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Digestive=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Endocrine=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Hematologic and Lymphatic=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Metabolic and Nutritional=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Musculoskeletal=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Neurologic=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Respiratory=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Skin and Hypersensitivy Reactions=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Special Senses=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Urogenital=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Miscellaneous=====
| |
|
| |
|
| |
|
| |
| <!--Postmarketing Experience-->
| |
|
| |
| |postmarketing=
| |
|
| |
| There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| =====Body as a Whole=====
| |
|
| |
|
| |
|
| |
| =====Cardiovascular=====
| |
|
| |
|
| |
|
| |
| =====Digestive=====
| |
|
| |
|
| |
|
| |
| =====Endocrine=====
| |
|
| |
|
| |
|
| |
| =====Hematologic and Lymphatic=====
| |
|
| |
|
| |
|
| |
| =====Metabolic and Nutritional=====
| |
|
| |
|
| |
|
| |
| =====Musculoskeletal=====
| |
|
| |
|
| |
|
| |
| =====Neurologic=====
| |
|
| |
|
| |
|
| |
| =====Respiratory=====
| |
|
| |
|
| |
|
| |
| =====Skin and Hypersensitivy Reactions=====
| |
|
| |
|
| |
|
| |
| =====Special Senses=====
| |
|
| |
|
| |
|
| |
| =====Urogenital=====
| |
|
| |
|
| |
|
| |
| =====Miscellaneous=====
| |
|
| |
|
| |
|
| |
| <!--Drug Interactions-->
| |
|
| |
| |drugInteractions=
| |
|
| |
| * Drug
| |
| :* Description
| |
|
| |
| <!--Use in Specific Populations-->
| |
|
| |
| |useInPregnancyFDA=
| |
| * '''Pregnancy Category'''
| |
|
| |
| |useInPregnancyAUS=
| |
| * '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
| |
|
| |
| There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
| |
|
| |
| |useInLaborDelivery=
| |
| There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
| |
|
| |
| |useInNursing=
| |
| There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
| |
|
| |
| |useInPed=
| |
| There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
| |
|
| |
| |useInGeri=
| |
| There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
| |
|
| |
| |useInGender=
| |
| There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
| |
|
| |
| |useInRace=
| |
| There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
| |
|
| |
| |useInRenalImpair=
| |
| There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
| |
|
| |
| |useInHepaticImpair=
| |
| There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
| |
|
| |
| |useInReproPotential=
| |
| There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
| |
|
| |
| |useInImmunocomp=
| |
| There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
| |
|
| |
| <!--Administration and Monitoring-->
| |
|
| |
| |administration=
| |
|
| |
| * Oral
| |
|
| |
| * Intravenous
| |
|
| |
| |monitoring=
| |
|
| |
| There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| * Description
| |
|
| |
| <!--IV Compatibility-->
| |
|
| |
| |IVCompat=
| |
|
| |
| There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Overdosage-->
| |
|
| |
| |overdose=
| |
|
| |
| ===Acute Overdose===
| |
|
| |
| ====Signs and Symptoms====
| |
|
| |
| * Description
| |
|
| |
| ====Management====
| |
|
| |
| * Description
| |
|
| |
| ===Chronic Overdose===
| |
|
| |
| There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Pharmacology-->
| |
|
| |
| <!--Drug box 2-->
| |
|
| |
| |drugBox=
| |
|
| |
|
| |
|
| |
| <!--Mechanism of Action-->
| |
|
| |
| |mechAction=
| |
|
| |
| *
| |
|
| |
| <!--Structure-->
| |
|
| |
| |structure=
| |
|
| |
| *
| |
|
| |
| : [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
| |
|
| |
| <!--Pharmacodynamics-->
| |
|
| |
| |PD=
| |
|
| |
| There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Pharmacokinetics-->
| |
|
| |
| |PK=
| |
|
| |
| There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Nonclinical Toxicology-->
| |
|
| |
| |nonClinToxic=
| |
|
| |
| There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Clinical Studies-->
| |
|
| |
| |clinicalStudies=
| |
|
| |
| There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--How Supplied-->
| |
|
| |
| |howSupplied=
| |
|
| |
| *
| |
|
| |
| <!--Patient Counseling Information-->
| |
|
| |
| |fdaPatientInfo=
| |
|
| |
| There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Precautions with Alcohol-->
| |
|
| |
| |alcohol=
| |
|
| |
| * Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
|
| |
| <!--Brand Names-->
| |
|
| |
| |brandNames=
| |
|
| |
| * ®<ref>{{Cite web | title = | url = }}</ref>
| |
|
| |
| <!--Look-Alike Drug Names-->
| |
|
| |
| |lookAlike=
| |
|
| |
| * A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>
| |
|
| |
| <!--Drug Shortage Status-->
| |
|
| |
| |drugShortage=
| |
| }}
| |
|
| |
| <!--Pill Image-->
| |
|
| |
| {{PillImage
| |
| |fileName=No image.jpg|This image is provided by the National Library of Medicine.
| |
| |drugName=
| |
| |NDC=
| |
| |drugAuthor=
| |
| |ingredients=
| |
| |pillImprint=
| |
| |dosageValue=
| |
| |dosageUnit=
| |
| |pillColor=
| |
| |pillShape=
| |
| |pillSize=
| |
| |pillScore=
| |
| }}
| |
|
| |
| <!--Label Display Image-->
| |
|
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
| |
| }}
| |
|
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
| |
| }}
| |
|
| |
| <!--Category-->
| |
|
| |
| [[Category:Drug]]
| |